Stay updated with breaking news from Binding Affinity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In a recent study posted to the bioRxiv* preprint server, researchers in Taiwan and the United States explore the resistance of a newly emergent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sub-variant BA.4.6 to the therapeutic monoclonal antibodies currently being used to treat coronavirus disease 2019 (COVID-19).
Researchers demonstrated that advances in modeling protein-ligand interactions using machine learning-based approaches are needed to exploit AlphaFold2 for antibiotic discovery better.
In a new study, researchers assessed the effects of N501Y mutation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein on binding to angiotensin-converting enzyme-2 (ACE-2).
Researchers performed a structural bioinformatics analysis to evaluate the binding energy of the SARS-CoV-2 Omicron variants of concern spike protein receptor-binding domain to human angiotensin-converting enzyme 2 receptor compared to other VOCs.
Researchers investigated the potential anti-COVID-19 activity of traditional Chinese medicine.